Conference Coverage

Novel agent shows promise against cat allergy


 

FROM AAAAI

Promising results

“The study is well designed and shows a reduction in drop of FEV1 in response to cat allergen provocation and a decreased AUC in cat SPT response over 4 months,” Jonathan A. Bernstein, MD, professor of medicine at the University of Cincinnati, said in an interview.

“These are very promising results, which show that REGN1908-1909 can be a novel treatment for cat-induced asthma, which is often the only sensitization patients have. And they love their cats – one-third of the U.S. population has a cat and one-third has a dog, and 50% have both,” noted Dr. Bernstein, who was not involved with the study.

“This novel study used our scientific knowledge of the cat allergen itself to design a targeted antibody-based treatment that demonstrates significant benefit even after the first shot,” added Edwin H. Kim, MD, director of the UNC Food Allergy Initiative at the University of North Carolina at Chapel Hill.

“This strategy has the potential to revolutionize not only our treatment of common environmental allergies but also other allergic diseases with well-described triggers, such as food and drug allergy,” Dr. Kim, who was not part of the study, said in an interview.

Dr. de Blay reported a financial relationship with Regeneron Pharmaceuticals, which sponsored the study. Dr. Bernstein and Dr. Kim have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Atopic dermatitis at 1 year links with persistent food allergies
MDedge Dermatology
Atopic dermatitis in egg-, milk-allergic kids may up anaphylaxis risk
MDedge Dermatology
Fast, aggressive eczema treatment linked to fewer food allergies by age 2
MDedge Dermatology
FDA okays Palforzia, first drug for peanut allergy in children
MDedge Dermatology
Study: Delays filling biologic prescriptions have consequences
MDedge Dermatology
Kids with food allergies the newest victims of COVID-19?
MDedge Dermatology
Daily Recap: Lifestyle vs. genes in breast cancer showdown; Big pharma sues over insulin affordability law
MDedge Dermatology
Hospitalizations for food anaphylaxis triple, but deaths down in United Kingdom
MDedge Dermatology
Peanut sublingual immunotherapy feasible and effective in toddlers
MDedge Dermatology
Mepolizumab reduced exacerbations in patients with asthma and atopy, depression comorbidities
MDedge Dermatology